Generic Drug Manufacturer Posts 340B Refund Notice

Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering the first through third quarters of 2019.

A HRSA audit in fiscal year 2020 found that PAI charged more than the 340B ceiling price and had an incorrect record in 340B OPAIS, the 340B program database. HRSA required PAI to repay covered entities for the overcharges. PAI’s public notice to covered entities, dated Jan. 25, does not mention the audit.

Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering first through third quarters of 2019.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report